Table 1.
Patient characteristics, n = 100
| Baseline parameter | Number (= %) |
|---|---|
| Sex | |
| Female sex | 46 |
| Male sex | 54 |
| Tumor type | |
| Non-small cell lung cancer | 42 |
| Breast cancer, triple negative | 3 |
| Breast cancer, Her2 positive | 4 |
| Breast cancer, other | 4 |
| Malignant melanoma | 12 |
| Small cell lung cancer | 9 |
| Renal cell cancer | 8 |
| Colorectal cancer | 10 |
| Other gastrointestinal cancer | 5 |
| Other primary tumors (bladder, head/neck) | 3 |
| Extracranial disease | |
| No extracranial metastases | 9 |
| Extracranial metastases | 91 |
| Bone metastases | 37 |
| Liver metastases | 38 |
| Lung/pleura metastases | 56 |
| Controlled primary tumor | 55 |
| Uncontrolled primary tumor* | 45 |
| Active organ sites incl. uncontrolled primary tumor: 0 | 5 |
| Active sites: 1** | 16 |
| Active sites: 2 | 25 |
| Active sites: 3 | 31 |
| Active sites: 4 | 17 |
| Active sites: > 4 | 6 |
| Brain metastases | |
| Single brain metastasis | 12 |
| Two or three brain metastases | 21 |
| Four or five brain metastases | 19 |
| Six to ten brain metastases | 27 |
| More than ten brain metastases | 21 |
| Synchronous brain metastases | 24 |
| Metachronous brain metastases, within 12 months | 37 |
| Metachronous brain metastases, 13–24 months | 11 |
| Metachronous brain metastases, 25–36 months | 11 |
| Metachronous brain metastases, 37–60 months | 8 |
| Metachronous brain metastases, > 60 months | 9 |
| Asymptomatic brain metastases | 9 |
| Symptom response to steroids | 64 |
| No response to steroids | 27 |
| Largest lesion diameter ≤ 2 cm | 48 |
| Largest lesion diameter 2.1–3.0 cm | 23 |
| Largest lesion diameter 3.1–4.0 cm | 19 |
| Largest lesion diameter > 4.0 cm | 10 |
| Karnofsky performance status (KPS) | |
| KPS 50 | 14 |
| KPS 60 | 30 |
| KPS 70 | 44 |
| KPS 80 | 8 |
| KPS 90 | 4 |
| Treatment | |
| Primary systemic treatment | 7 |
| Surgery with post-operative cavity radiotherapy | 2 |
| Stereotactic single fraction radiosurgery | 6 |
| Stereotactic fractionated radiotherapy | 6 |
| Whole-brain radiotherapy, 20 Gy in 5 fractions | 12 |
| Whole-brain radiotherapy, 30 Gy in 10 fracions | 64 |
| Whole-brain radiotherapy, higher dose than 30 Gy | 3 |
| Any systemic therapy after diagnosis of brain metastases | 34 |
| Age, years | |
| < 60 | 18 |
| 60–69 | 40 |
| 70–79 | 35 |
| 80–89 | 5 |
| ≥ 90 | 2 |
| Extracranial score (EC-S; LDH, albumin, extracranial involvement of at least 2 organs, e.g. bone + liver) | |
| All 3 adverse factors present | 9 |
| Two of these factors present | 42 |
| One of these factors present | 36 |
| No adverse factors present | 13 |
| LabBM score (5 blood test results) | |
| LabBM score 0 (favorable) | 15 |
| LabBM score 0.5 | 7 |
| LabBM score 1.0 | 17 |
| LabBM score 1.5 | 21 |
| LabBM score 2.0 | 14 |
| LabBM score 2.5 | 15 |
| LabBM score 3.0 | 9 |
| LabBM score 3.5 | 2 |
LDH lactate dehydrogenase
*progressive after previous treatment or not yet treated
**examples uncontrolled primary tumor or liver metastases, irrespective of number and size